Does Zydus’ 50% stake acquisition in Sterling Biotech reflect a broader move of formulations companies to secure API supplies or acceleration of API segment restructuring begun by a couple of private equity (PE) funds?
The active pharmaceutical ingredients (API) segment is witnessing a gradual restructuring with an increasing number of large Indian companies expanding their presence via new facilities or stake acquisitions in existing firms.
The latest to join the bandwagon is Zydus Lifesciences Limited, which via subsidiary Zydus Animal Health and Investments Ltd, has acquired a 50% stake in gelatin, dicalcium phosphate and...
One Phase III trial hits but a second study misses by a mile.
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.
